Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

he end-user customer.  Cadence recognized this deferred revenue during the period as it determined it had obtained sufficient product return history as of January 1, 2013, to reasonably estimate future wholesaler returns. As a result, the company recorded a one-time adjustment during the three months ended March 31, 2013, to recognize deferred revenue on previously shipped product, resulting in additional net revenue of $2.6 million and cost of sales of $0.9 million, for a net gross margin impact of $1.7 million.

For the three months ended March 31, 2013, Cadence reported a net loss of $1.4 million, or $0.02 per share, compared to a net loss of $22.7 million, or $0.27 per share, for the comparable period in 2012. Included in the company's net loss for the three months ended March 31, 2013, was a gain of $7.7 million Cadence recorded on the waiver, termination and sale of its Incline assets in January 2013, for which the company received cash payments totaling $14.6 million. Excluding the $7.7 million gain from the Incline transaction, and the $1.7 million gross margin impact from the change in the company's revenue recognition accounting estimate, Cadence's net loss for the three months ended March 31, 2013, was $10.8 million, or $0.13 per share.

Gross margin for the three months ended March 31, 2013, was 65%, compared to 47% for the comparable period in 2012. The increase in margin was primarily a result of higher freight costs incurred during the first quarter of 2012 that were not incurred in 2013, the impact of price increases implemented in July 2012 and January 2013, and a one-time credit of $0.3 million recorded during the three months ended March 31, 2013, in connection with the termination of the company's supply agreement with Baxter. Operating expenses, including patent amortization, decreased $2.0 million for the three months ended March 31, 2013, to $23.4 million, from $25.4 million for the same period in 2012. This decrease in
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)...  The Myeloma Crowd Research Initiative (MCRI) completed ... proposals that will now be evaluated for further ... validated funding initiative uncovering solutions for high-risk multiple ... MCRI included preliminary vetting by the Scientific Advisory ... of innovative projects focusing on high-risk myeloma, we ...
(Date:3/31/2015)... CA (PRWEB) March 31, 2015 This ... Professors from the top U.S and International Medical Schools ... their latest research on the application of stem cell ... The symposium is organized and funded by the ... nonprofit that has been convening intimate meetings of top ...
(Date:3/31/2015)... Lighthouse Information Systems, Inc., a ... California, Oregon, Washington and clients across the US, ... Acquisition (M&A) Integration Services offering, effective immediately. ... and M&A Integration Practice Leader at Lighthouse, explains, ... of M&A initiatives fail to achieve their intended ...
(Date:3/30/2015)... , March 30, 2015  Multiple new research ... affect several important health factors. From their impact on ... their positive effect on both gut health and vascular ... (EB) detail our latest understanding of walnuts, inner workings. ... Boston , this annual meeting attracts an international ...
Breaking Biology Technology:Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4
... Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch --EXTON, Pa., ... reported today its financial results for the fourth quarter and ... include:Operational: , , , ... Inc. (Lev) in October 2008; , ...
... Feb. 24 Mach One Corporation (Pink Sheets: MNCN), ... purchase of Ceres Organic Harvest, Inc. an organic grain ... feed and dairy industries. Ceres Organic Harvest had 2008 ... the stock of Ceres for $8 million in a ...
... (USA) Inc ("MINDSET") a company privately held by MPM ... received a Notice of Allowance in Europe related to ... for the prevention and treatment of memory loss. Drugs ... been approved for the treatment of type II diabetes ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc. 2Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss 2Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss 3
(Date:3/12/2015)... -- IriTech, a leading iris based identity management technology ... Design Network, announced today that the Chief Minister ... MK2120U device during a launching event of Andhra Pradesh ... The iris scanner is manufactured by U.S. based ... India through its Indian partner, Biometronic Technology, ...
(Date:3/11/2015)... March 11, 2015   The Sync Project™ ... to scientifically measure and harness music to improve ... biometrics and objective measurements of physiology, enabling the ... scale in large populations. It is designed for ... clinicians perform rigorous studies and accelerate the discovery ...
(Date:3/5/2015)... In Brazil , cloud computing is fast ... and 42 percent planning to invest in them by the ... the companies will be investing in these solutions for the ... the region are currently opting for the private cloud model, ... attention in the coming years. This trend is in line ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... centuries, humans have been exploring, researching, and, in some ... life spans, and obtain immortality. Biologists, doctors, spiritual ... the most well-known examples being the legendary search by ... the key to longevity may not lie in a ...
... Victor Gibeault , a cooperative extension specialist, emeritus, ... 2013 United States Golf Association ( USGA ) Green ... honor those persons who deserve special recognition for distinguished ... award will be presented to Gibeault on Feb. 8, ...
... synchrotron-based imaging techniques to identify previously unseen anatomy preserved in ... old lizard skin identified the presence of teeth (invisible to ... animal was more than just a skin moult. This was ... universe, x-rays generated by a synchrotron. Dr Phil ...
Cached Biology News:Do palm trees hold the key to immortality? 2Do palm trees hold the key to immortality? 3Do palm trees hold the key to immortality? 4UC Riverside turfgrass specialist receives high honor 2Prehistoric ghosts revealing new details 2
...
... from vaccinia virus is a type I ... negative superhelical turns (also called right- and ... product of the reaction is a covalently ... negative superhelical turns. DNA Topoisomerase I does ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Biology Products: